Stock listing
KRX:397030 Aprilbio Co., Ltd. (에이프릴바이오) 주가
Follow Aprilbio Co., Ltd. into a list and get an email when it puts out news.
Share price · KRX:397030
₩12,710 KRW +1,260 (+11.0%)
Close on Nov 20, 2026
- Day range
- ₩12,510 – ₩13,190 KRWNov 20, 2026
- Volume
- 140,888 sharesNov 20, 2026
- Market cap
- ₩297.6B KRWAt the close on Nov 20, 2026 · price × 23.41M shares outstanding
- 52-week range
- ₩10,310 – ₩76,700 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩3.87B KRWMedian day 167,840 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:397030 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩12,710 | +1,260 | +11.0% | ₩12,870 | ₩13,190 | ₩12,510 | 140,888 | |
| ₩11,450 | +40 | +0.4% | ₩11,570 | ₩12,120 | ₩11,230 | 65,861 | |
| ₩11,410 | 0 | 0.0% | ₩11,110 | ₩11,960 | ₩11,110 | 82,838 | |
| ₩11,410 | -700 | -5.8% | ₩12,130 | ₩12,310 | ₩11,350 | 101,999 | |
| ₩12,110 | -40 | -0.3% | ₩12,260 | ₩13,310 | ₩12,070 | 166,255 | |
| ₩12,150 | -250 | -2.0% | ₩12,310 | ₩12,780 | ₩12,000 | 124,906 | |
| ₩12,400 | +760 | +6.5% | ₩11,500 | ₩12,500 | ₩11,470 | 142,541 | |
| ₩11,640 | +820 | +7.6% | ₩11,200 | ₩11,740 | ₩11,100 | 119,844 | |
| ₩10,820 | +120 | +1.1% | ₩10,560 | ₩11,460 | ₩10,380 | 205,289 | |
| ₩10,700 | -680 | -6.0% | ₩10,510 | ₩10,990 | ₩10,310 | 198,560 | |
| ₩11,380 | -230 | -2.0% | ₩11,810 | ₩12,450 | ₩11,290 | 213,510 | |
| ₩11,610 | +90 | +0.8% | ₩11,540 | ₩11,670 | ₩10,760 | 155,633 | |
| ₩11,520 | -340 | -2.9% | ₩11,720 | ₩11,950 | ₩11,330 | 124,101 | |
| ₩11,860 | +50 | +0.4% | ₩11,390 | ₩12,000 | ₩11,390 | 73,789 | |
| ₩11,810 | -590 | -4.8% | ₩12,210 | ₩12,350 | ₩11,700 | 248,969 | |
| ₩12,400 | 0 | 0.0% | ₩13,110 | ₩13,160 | ₩12,290 | 217,303 | |
| ₩12,400 | +60 | +0.5% | ₩12,500 | ₩12,900 | ₩12,330 | 99,930 | |
| ₩12,340 | -60 | -0.5% | ₩12,420 | ₩13,010 | ₩12,340 | 81,915 | |
| ₩12,400 | -350 | -2.7% | ₩12,340 | ₩12,850 | ₩12,330 | 56,996 | |
| ₩12,750 | -350 | -2.7% | ₩12,730 | ₩12,940 | ₩12,550 | 65,680 | |
| ₩13,100 | -400 | -3.0% | ₩13,360 | ₩13,560 | ₩13,100 | 78,318 | |
| ₩13,500 | +300 | +2.3% | ₩13,320 | ₩13,910 | ₩13,320 | 65,056 | |
| ₩13,200 | -350 | -2.6% | ₩13,520 | ₩13,630 | ₩12,870 | 81,918 | |
| ₩13,550 | +710 | +5.5% | ₩12,300 | ₩13,550 | ₩12,300 | 98,860 | |
| ₩12,840 | +810 | +6.7% | ₩12,440 | ₩13,220 | ₩12,180 | 183,012 | |
| ₩12,030 | -880 | -6.8% | ₩12,390 | ₩12,570 | ₩11,810 | 196,175 | |
| ₩12,910 | +20 | +0.2% | ₩13,010 | ₩13,480 | ₩12,680 | 156,646 | |
| ₩12,890 | -520 | -3.9% | ₩13,060 | ₩13,290 | ₩12,450 | 229,840 | |
| ₩13,410 | -1,150 | -7.9% | ₩14,450 | ₩14,660 | ₩13,360 | 253,360 | |
| ₩14,560 | -1,190 | -7.6% | ₩15,220 | ₩15,340 | ₩14,510 | 386,672 | |
| ₩15,750 | -280 | -1.7% | ₩16,170 | ₩16,290 | ₩15,750 | 237,260 | |
| ₩16,030 | -990 | -5.8% | ₩16,440 | ₩16,940 | ₩15,860 | 579,641 | |
| ₩17,020 | -4,280 | -20.1% | ₩19,560 | ₩19,640 | ₩16,925 | 1,657,247 | |
| ₩21,300 | +1,100 | +5.4% | ₩19,980 | ₩21,450 | ₩19,620 | 322,747 | |
| ₩20,200 | +1,510 | +8.1% | ₩18,530 | ₩20,850 | ₩18,320 | 459,564 | |
| ₩18,690 | -10 | -0.1% | ₩18,510 | ₩18,920 | ₩17,760 | 178,969 | |
| ₩18,700 | +590 | +3.3% | ₩18,600 | ₩19,540 | ₩18,360 | 281,259 | |
| ₩18,110 | +310 | +1.7% | ₩17,810 | ₩18,360 | ₩17,720 | 67,857 | |
| ₩17,800 | -600 | -3.3% | ₩18,470 | ₩18,570 | ₩17,800 | 113,333 | |
| ₩18,400 | +120 | +0.7% | ₩18,200 | ₩18,950 | ₩18,150 | 179,926 | |
| ₩18,280 | +240 | +1.3% | ₩17,860 | ₩18,370 | ₩17,600 | 187,265 | |
| ₩18,040 | +360 | +2.0% | ₩17,630 | ₩18,270 | ₩17,550 | 122,791 | |
| ₩17,680 | +500 | +2.9% | ₩17,180 | ₩17,690 | ₩16,800 | 111,232 | |
| ₩17,180 | +330 | +2.0% | ₩16,800 | ₩17,700 | ₩16,800 | 147,841 | |
| ₩16,850 | -280 | -1.6% | ₩16,720 | ₩17,360 | ₩16,450 | 128,267 | |
| ₩17,130 | -120 | -0.7% | ₩16,720 | ₩17,390 | ₩16,720 | 103,569 | |
| ₩17,250 | -270 | -1.5% | ₩17,160 | ₩17,250 | ₩16,730 | 101,617 | |
| ₩17,520 | -50 | -0.3% | ₩17,480 | ₩17,800 | ₩17,440 | 62,603 | |
| ₩17,570 | -610 | -3.4% | ₩18,120 | ₩18,410 | ₩17,570 | 125,059 | |
| ₩18,180 | +380 | +2.1% | ₩17,810 | ₩18,520 | ₩17,460 | 167,918 | |
| ₩17,800 | +1,030 | +6.1% | ₩17,270 | ₩17,970 | ₩17,150 | 208,197 | |
| ₩16,770 | -350 | -2.0% | ₩17,160 | ₩17,300 | ₩16,600 | 199,522 | |
| ₩17,120 | -900 | -5.0% | ₩17,480 | ₩17,970 | ₩17,110 | 167,762 | |
| ₩18,020 | +110 | +0.6% | ₩17,750 | ₩18,490 | ₩17,650 | 191,781 | |
| ₩17,910 | -640 | -3.5% | ₩18,190 | ₩18,190 | ₩17,030 | 763,903 | |
| ₩18,550 | -720 | -3.7% | ₩19,210 | ₩19,410 | ₩18,410 | 314,015 | |
| ₩19,270 | +80 | +0.4% | ₩19,000 | ₩19,660 | ₩18,930 | 252,748 | |
| ₩19,190 | -280 | -1.4% | ₩19,650 | ₩19,940 | ₩19,050 | 263,698 | |
| ₩19,470 | -470 | -2.4% | ₩19,570 | ₩19,690 | ₩18,470 | 267,065 | |
| ₩19,940 | +100 | +0.5% | ₩20,050 | ₩20,400 | ₩19,590 | 285,215 | |
| ₩19,840 | -1,410 | -6.6% | ₩20,950 | ₩21,100 | ₩19,130 | 569,969 | |
| ₩21,250 | -5,050 | -19.2% | ₩22,900 | ₩23,200 | ₩20,700 | 1,205,024 |
Splits
1 split · KRX:397030 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split |
- Ticker
- KRX:397030
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- KRX
- Currency
- KRW
What changed lately
Latest news release · Jun 25, 2026
Aprilbio Co Denies Media Report On Acquisition By Taekwang Industrial
Latest news
Aprilbio Co Denies Media Report On Acquisition By Taekwang Industrial
Jun 24, 2026
Closed ₩38,500 (-3.0%) on Jun 25, 2026
Aprilbio Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 1 in the last 12 months · 1 in all · newest Jun 25, 2026 · oldest 2026
Valuation
Price/book 3.1× against a median of 1.3×: 7th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩216.9B KRW
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Aprilbio Co., Ltd. · KRX:397030 | US$221.1M | US$161.1M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | n/a |
| Enanta Pharmaceuticals, Inc. · NASDAQ:ENTA | US$222.2M | US$82.43M | n/a | 1.3× | n/a | 2.8× | −108.3% | 0.7× | 1.11 |
| Clover Biopharmaceuticals Ltd. · HKEX:2197 | US$222.0M | US$206.5M | n/a | 403× | n/a | n/a | n/a | n/a | n/a |
| Northwest Biotherapeutics, Inc. · OTC:NWBO | US$220.0M | US$283.8M | n/a | 99.4× | n/a | n/a | n/a | n/a | 0.90 |
| Keros Therapeutics, Inc. · NASDAQ:KROS | US$219.7M | −US$24.67M | n/a | −0.6× | n/a | 0.8× | −152.7% | 0.1× | 1.16 |
| Immuneering Corporation · NASDAQ:IMRX | US$218.7M | US$160.5M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.17 |
| Allogene Therapeutics, Inc. · NASDAQ:ALLO | US$217.5M | −US$7.44M | n/a | −1.6× | n/a | 0.6× | n/a | 0.2× | 1.93 |
| ProKidney Corp. · NASDAQ:PROK | US$217.3M | US$77.56M | n/a | 100× | n/a | n/a | n/a | n/a | 1.61 |
| Pyxis Oncology, Inc. · NASDAQ:PYXS | US$216.5M | US$160.9M | n/a | n/a | n/a | 5.2× | n/a | 0.0× | 0.89 |
| Oryzon Genomics SA · BME:ORY | US$216.4M | US$206.7M | n/a | n/a | n/a | 1.6× | n/a | 0.1× | n/a |
| Rocket Pharmaceuticals, Inc. · NASDAQ:RCKT | US$214.1M | −US$25.02M | n/a | n/a | n/a | 0.7× | n/a | 0.1× | 1.72 |
| Median of the others | US$218.1M | US$121.4M | 50.3× | 1.3× | −130.5% | 0.1× | 1.17 |
Forecasts
Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.
- Price target
- 100000.00 KRW · Analysts' mean
- EPS, year to Dec 2026
- -1188.00 · 1 analyst
- Revenue, year to Dec 2026
- 13B · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Sanghoon Cha | Chief Executive Officer |
| Byungung Hur | Director, R&D Center |
| Jaekyu Han | Director, R&D Center |
| Susan Chi | Managing Director, R&D Center |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.17B | 27.5B | 0 | 200.0M | 23.4B | 150.0M | |
| Gross profit | 2.17B | 27.5B | 200.0M | 23.4B | 150.0M | ||
| Research and development | 4.02B | 3.20B | 8.04B | 6.92B | 13.9B | 6.78B | |
| Selling, general and administrative | 754.7M | 6.73B | 4.68B | 4.16B | 1.39B | 378.0M | |
| Operating income | -7.26B | 16.7B | -13.4B | -11.5B | 4.45B | -9.19B | |
| Depreciation and amortization | 689.6M | 705.6M | 674.4M | 593.4M | 487.3M | 361.4M | |
| EBITDA | -6.57B | 17.5B | -12.7B | -10.9B | 4.93B | -8.83B | |
| Interest expense | 618.9M | 1.42B | 930.5M | 29.8M | 2.11B | 1.28B | |
| Income before tax | -9.73B | 20.0B | -14.1B | -8.96B | -52.7B | -10.3B | |
| Net income | -9.73B | 20.0B | -14.1B | -8.96B | -52.7B | -10.2B | |
| Earnings per share, basic | -419.16 | 891.67 | -654.93 | -424.17 | -2,506.63 | -487.79 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 7.07B | 3.35B | 6.59B | 7.28B | 24.4B | 10.1B | |
| Short-term investments | 85.7B | 91.1B | 57.0B | 61.5B | 30.0B | 7.00B | |
| Receivables | 1.47B | 480.0M | 255.8M | 4.29B | 51.4M | ||
| Current assets | 94.7B | 96.6B | 66.7B | 69.4B | 59.4B | 18.0B | |
| Property, plant and equipment | 1.20B | 1.34B | 1.34B | ||||
| Total assets | 97.1B | 99.6B | 79.7B | 71.1B | 61.4B | 19.4B | |
| Current liabilities | 541.5M | 8.48B | 21.7B | 1.79B | 4.05B | 33.1B | |
| Total liabilities | 803.8M | 8.61B | 22.0B | 1.90B | 4.21B | 33.2B | |
| Shareholders' equity | 96.3B | 91.0B | 57.7B | 69.2B | 57.2B | -13.8B | |
| Shares outstanding | 23.2M | 22.4M | 21.6M | 21.1M | 21.0M | 21.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -3.34B | 22.0B | -10.1B | -6.70B | 3.25B | -7.33B |
| Capital spending | -287.8M | -445.3M | -512.0M | -89.6M | -705.8M | -479.8M |
| Free cash flow | -3.63B | 21.5B | -10.6B | -6.79B | 2.55B | -7.81B |
| Cash from investing | -22.8B | -7.05B | -31.6B | |||
| Cash from financing | -2.51B | 16.3B | 20.3B | |||
| Share buybacks | 1.10B | 1.76B | 20.6B | |||
| Change in cash | 3.73B | -3.24B | -697.3M | -17.1B | 14.2B | 3.51B |
Cap table
Built by 6ix from Aprilbio Co., Ltd.’s releases
- Common shares
- 23,413,826
- Fully diluted
- 23,413,826
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 23,413,826 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 23,413,826 |
Log in to ask 6ix AI your own questions about Aprilbio Co., Ltd.